Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer

BACKGROUND: The loss of PTEN function presents in up to 50% of late-stage prostate cancers, and is therefore a potential target for therapeutics. PTEN-deficient cells depend on de novo pyrimidine synthesis, a feature which can present a vulnerability. METHODS: We utilized in vitro growth assays and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozturk, Sait, Mathur, Deepti, Zhou, Royce W., Mulholland, David, Parsons, Ramon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666085/
https://www.ncbi.nlm.nih.gov/pubmed/32661432
http://dx.doi.org/10.1038/s41391-020-0251-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666085/
https://www.ncbi.nlm.nih.gov/pubmed/32661432
http://dx.doi.org/10.1038/s41391-020-0251-1

Ejemplares similares